Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer

Xianglin L. Du, Rui Xia, Chih Chin Liu, Janice N. Cormier, Yan Xing, Dale Sharon Hardy, Wenyaw Chan, Keith Burau

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

BACKGROUND: The purpose of this study was to determine the risk of chemotherapy-associated cardiac toxicity, including cardiac dysrhythmia, cardiomyopathy, congestive heart failure, ischemic heart disease, and conduction disorders among breast cancer patients with up to 16 years of follow-up. METHODS: The authors studied 19,478 women aged >65 diagnosed with breast cancer in 1991-1997 from 16 regions in the Surveillance, Epidemiology, and End Results program. Incidence density and cumulative incidence of cardiac toxicities were calculated, and the time-to-event (cardiac toxicity) analysis was conducted by using the Cox hazard regression model. RESULTS: The excess cumulative incidence of congestive heart failure in Year 10 among patients receiving anthracycline-containing chemotherapy compared with patients without chemotherapy was 4.7% (31.9% vs 27.2%). After adjusting for patient and tumor characteristics, patients receiving anthracyclines were 25% more likely to have congestive heart failure compared with those without chemotherapy (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.07-1.46). Those receiving other agents did not have a significantly elevated risk of developing congestive heart failure. The adjusted risk of cardiomyopathy was 2-fold higher in women who received anthracyclines (HR, 1.95; 95% CI, 1.44-2.62) and was 16% higher in those receiving other agents (HR, 1.16; 95% CI, 0.97-1.39) compared with those without chemotherapy. The increased risk for developing congestive heart failure, cardiomyopathy, and cardiac dysrhythmias in association with chemotherapy were similar after adjusting for hypertension and diabetes. The risk of ischemic heart disease and conduction disorders were not significantly different among the 3 groups. CONCLUSIONS: Anthracycline-containing chemotherapy regimens were associated with an increased risk of congestive heart failure, cardiomyopathy, and cardiac dysrhythmias, but not significantly associated with ischemic heart disease or conduction disorders.

Original languageEnglish (US)
Pages (from-to)5296-5308
Number of pages13
JournalCancer
Volume115
Issue number22
DOIs
StatePublished - Nov 15 2009

Fingerprint

Anthracyclines
Breast Neoplasms
Heart Failure
Drug Therapy
Cardiomyopathies
Myocardial Ischemia
Cardiac Arrhythmias
Confidence Intervals
Incidence
SEER Program
Cardiotoxicity
Proportional Hazards Models
Hypertension
Neoplasms

Keywords

  • Breast cancer
  • Cardiotoxicity
  • Chemotherapy
  • Congestive heart failure
  • Medicare

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Du, X. L., Xia, R., Liu, C. C., Cormier, J. N., Xing, Y., Hardy, D. S., ... Burau, K. (2009). Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer, 115(22), 5296-5308. https://doi.org/10.1002/cncr.24621

Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. / Du, Xianglin L.; Xia, Rui; Liu, Chih Chin; Cormier, Janice N.; Xing, Yan; Hardy, Dale Sharon; Chan, Wenyaw; Burau, Keith.

In: Cancer, Vol. 115, No. 22, 15.11.2009, p. 5296-5308.

Research output: Contribution to journalArticle

Du, XL, Xia, R, Liu, CC, Cormier, JN, Xing, Y, Hardy, DS, Chan, W & Burau, K 2009, 'Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer', Cancer, vol. 115, no. 22, pp. 5296-5308. https://doi.org/10.1002/cncr.24621
Du, Xianglin L. ; Xia, Rui ; Liu, Chih Chin ; Cormier, Janice N. ; Xing, Yan ; Hardy, Dale Sharon ; Chan, Wenyaw ; Burau, Keith. / Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. In: Cancer. 2009 ; Vol. 115, No. 22. pp. 5296-5308.
@article{52946ae4eeda4efdb5472b82c74682be,
title = "Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer",
abstract = "BACKGROUND: The purpose of this study was to determine the risk of chemotherapy-associated cardiac toxicity, including cardiac dysrhythmia, cardiomyopathy, congestive heart failure, ischemic heart disease, and conduction disorders among breast cancer patients with up to 16 years of follow-up. METHODS: The authors studied 19,478 women aged >65 diagnosed with breast cancer in 1991-1997 from 16 regions in the Surveillance, Epidemiology, and End Results program. Incidence density and cumulative incidence of cardiac toxicities were calculated, and the time-to-event (cardiac toxicity) analysis was conducted by using the Cox hazard regression model. RESULTS: The excess cumulative incidence of congestive heart failure in Year 10 among patients receiving anthracycline-containing chemotherapy compared with patients without chemotherapy was 4.7{\%} (31.9{\%} vs 27.2{\%}). After adjusting for patient and tumor characteristics, patients receiving anthracyclines were 25{\%} more likely to have congestive heart failure compared with those without chemotherapy (hazard ratio [HR], 1.25; 95{\%} confidence interval [CI], 1.07-1.46). Those receiving other agents did not have a significantly elevated risk of developing congestive heart failure. The adjusted risk of cardiomyopathy was 2-fold higher in women who received anthracyclines (HR, 1.95; 95{\%} CI, 1.44-2.62) and was 16{\%} higher in those receiving other agents (HR, 1.16; 95{\%} CI, 0.97-1.39) compared with those without chemotherapy. The increased risk for developing congestive heart failure, cardiomyopathy, and cardiac dysrhythmias in association with chemotherapy were similar after adjusting for hypertension and diabetes. The risk of ischemic heart disease and conduction disorders were not significantly different among the 3 groups. CONCLUSIONS: Anthracycline-containing chemotherapy regimens were associated with an increased risk of congestive heart failure, cardiomyopathy, and cardiac dysrhythmias, but not significantly associated with ischemic heart disease or conduction disorders.",
keywords = "Breast cancer, Cardiotoxicity, Chemotherapy, Congestive heart failure, Medicare",
author = "Du, {Xianglin L.} and Rui Xia and Liu, {Chih Chin} and Cormier, {Janice N.} and Yan Xing and Hardy, {Dale Sharon} and Wenyaw Chan and Keith Burau",
year = "2009",
month = "11",
day = "15",
doi = "10.1002/cncr.24621",
language = "English (US)",
volume = "115",
pages = "5296--5308",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "22",

}

TY - JOUR

T1 - Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer

AU - Du, Xianglin L.

AU - Xia, Rui

AU - Liu, Chih Chin

AU - Cormier, Janice N.

AU - Xing, Yan

AU - Hardy, Dale Sharon

AU - Chan, Wenyaw

AU - Burau, Keith

PY - 2009/11/15

Y1 - 2009/11/15

N2 - BACKGROUND: The purpose of this study was to determine the risk of chemotherapy-associated cardiac toxicity, including cardiac dysrhythmia, cardiomyopathy, congestive heart failure, ischemic heart disease, and conduction disorders among breast cancer patients with up to 16 years of follow-up. METHODS: The authors studied 19,478 women aged >65 diagnosed with breast cancer in 1991-1997 from 16 regions in the Surveillance, Epidemiology, and End Results program. Incidence density and cumulative incidence of cardiac toxicities were calculated, and the time-to-event (cardiac toxicity) analysis was conducted by using the Cox hazard regression model. RESULTS: The excess cumulative incidence of congestive heart failure in Year 10 among patients receiving anthracycline-containing chemotherapy compared with patients without chemotherapy was 4.7% (31.9% vs 27.2%). After adjusting for patient and tumor characteristics, patients receiving anthracyclines were 25% more likely to have congestive heart failure compared with those without chemotherapy (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.07-1.46). Those receiving other agents did not have a significantly elevated risk of developing congestive heart failure. The adjusted risk of cardiomyopathy was 2-fold higher in women who received anthracyclines (HR, 1.95; 95% CI, 1.44-2.62) and was 16% higher in those receiving other agents (HR, 1.16; 95% CI, 0.97-1.39) compared with those without chemotherapy. The increased risk for developing congestive heart failure, cardiomyopathy, and cardiac dysrhythmias in association with chemotherapy were similar after adjusting for hypertension and diabetes. The risk of ischemic heart disease and conduction disorders were not significantly different among the 3 groups. CONCLUSIONS: Anthracycline-containing chemotherapy regimens were associated with an increased risk of congestive heart failure, cardiomyopathy, and cardiac dysrhythmias, but not significantly associated with ischemic heart disease or conduction disorders.

AB - BACKGROUND: The purpose of this study was to determine the risk of chemotherapy-associated cardiac toxicity, including cardiac dysrhythmia, cardiomyopathy, congestive heart failure, ischemic heart disease, and conduction disorders among breast cancer patients with up to 16 years of follow-up. METHODS: The authors studied 19,478 women aged >65 diagnosed with breast cancer in 1991-1997 from 16 regions in the Surveillance, Epidemiology, and End Results program. Incidence density and cumulative incidence of cardiac toxicities were calculated, and the time-to-event (cardiac toxicity) analysis was conducted by using the Cox hazard regression model. RESULTS: The excess cumulative incidence of congestive heart failure in Year 10 among patients receiving anthracycline-containing chemotherapy compared with patients without chemotherapy was 4.7% (31.9% vs 27.2%). After adjusting for patient and tumor characteristics, patients receiving anthracyclines were 25% more likely to have congestive heart failure compared with those without chemotherapy (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.07-1.46). Those receiving other agents did not have a significantly elevated risk of developing congestive heart failure. The adjusted risk of cardiomyopathy was 2-fold higher in women who received anthracyclines (HR, 1.95; 95% CI, 1.44-2.62) and was 16% higher in those receiving other agents (HR, 1.16; 95% CI, 0.97-1.39) compared with those without chemotherapy. The increased risk for developing congestive heart failure, cardiomyopathy, and cardiac dysrhythmias in association with chemotherapy were similar after adjusting for hypertension and diabetes. The risk of ischemic heart disease and conduction disorders were not significantly different among the 3 groups. CONCLUSIONS: Anthracycline-containing chemotherapy regimens were associated with an increased risk of congestive heart failure, cardiomyopathy, and cardiac dysrhythmias, but not significantly associated with ischemic heart disease or conduction disorders.

KW - Breast cancer

KW - Cardiotoxicity

KW - Chemotherapy

KW - Congestive heart failure

KW - Medicare

UR - http://www.scopus.com/inward/record.url?scp=70449372114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449372114&partnerID=8YFLogxK

U2 - 10.1002/cncr.24621

DO - 10.1002/cncr.24621

M3 - Article

C2 - 19672997

AN - SCOPUS:70449372114

VL - 115

SP - 5296

EP - 5308

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 22

ER -